PURPOSE: Finasteride is an inhibitor of human 5alpha-reductase, which results in a decrease in plasma and intraprostatic dihydrotestosterone(DHT) level. We investigated the changes of prostate volume(PV), transitional zone volume(TV), and PSA during and after administration of finasteride. MATERIALS AND METHODS: From 1995, 32 BPH patients treated with finasteride underwent surveillance after cessation of finasteride. Surveillance included measurements of PV, TV and PSA every 3 to 6 months. The mean age of the patients was 66.7 years(57-73). The mean duration of treatment and cessation were 8.6 months(6-12) and 8.0 months(6-12), respectively. The changes in PV, TV, and PSA were compared. RESULTS: The mean initial PV, TV, PSA were 45.7cc, 22.5cc, 2.72ng/ml, respectively. After treatment, PV, TV, PSA were reduced to 72.7%, 67.1%, 64.7% and 68.0%, 61.4%, 57.3% and 59.4%, 55.0%, 52.5% of the original values at 3, 6 and 12 months, respectively. The reduction rate was maximum after the first 3 months(p=0.001). After discontinuing finasteride, PV, TV, PSA recovered to 71.0%, 71.2% 63.9% and 84.0%, 82.3%, 67.6% and 90.4%, 85.1%, 74.1% at 3, 6 and 12 months, respectively. The recovery rates of PV and TV after 3 and 6 months were equal. However, recovery rate of PSA was maximum at 3 months and after then, constant until 12 months. CONCLUSIONS: During first 3 months` treatment, the decreasing rates of PV, TV and PSA were very considerable, after then, reduced. After cessation of medication the recovery rates of PV, TV were constant during first 6 months but PSA was maximum at first 3 months. The changes in clinical parameters during administration were fully recovered but it took slightly longer periods after cessation compared to those during of treatment. PSA is probably a predictor in the assessment of volume changes.
Finasteride* ; Humans ; Plasma ; Prostate*

No abstract available.
Animals ; Finasteride* ; Rats* ; Spermatogenesis*

No abstract available.
Alopecia* ; Dutasteride* ; Finasteride*

No abstract available.
Finasteride* ; Risk Factors ; Venous Thrombosis*

No abstract available.
Animals ; Castration* ; Finasteride* ; Prostate* ; Rats*

Oral finasteride(Propecia(R)), 1mg/day, has been widely used as an effective treatment for male androgenetic alopecia since it had been approved by the Food and Drug Administration(FDA) of U.S. in December 1997. Gynecomastia has been one of the most common adverse effects in the patients who were taking 5mg of oral finasteride(Proscar(R)). Recently, several cases of unilateral or bilateral finasteride induced gynecomastia have also been reported in 1mg of oral finasteride(Propecia(r)). We report two cases of finasteride(Propecia(R)) induced painful bilateral gynecomastia, which are the first published documentations in Korea.
Alopecia ; Documentation ; Finasteride ; Gynecomastia* ; Humans ; Korea ; Male

No abstract available.
Female ; Finasteride ; Hair ; Humans ; Pilot Projects

BACKGROUND: Anagen Effluvium is one of the typical side effects of chemotherapy, which is completely reversible. However, there are growing numbers of chemotherapy-induced permanent alopecia (CIPAL) which are characterized by an absence of or an incomplete hair regrowth 6-months beyond the cessation of chemotherapy. OBJECTIVE: The purpose of this study is to reveal the clinical characteristics of CIPAL patients. METHODS: We retrospectively included 54 cases with CIPAL whom are being diagnosed from January 1996 to December 2011. The age, gender, duration of alopecia, familial history of alopecia, past medical history (including the types of chemotherapy agents), clinical patterns of alopecia and treatment responses were all analyzed. RESULTS: There was no sexual predominance. Mean age of the onset was 31.5 years old. There were two morphological types of CIPAL: diffused (69%) and androgenetic patterned (31%). Cyclophosphamide is the most commonly used chemotherapy agent in both types of alopecia. The response to treatment with topical minoxidil and/or oral finasteride was rather restrictive. CONCLUSION: In some cases of hair loss due to chemotherapic agents, the hair regrowths after the cessation of chemotherapy are rather restricted. This study demonstrated the clinical features of CIPAL. The patterns of CIPAL are either diffused or androgenetic. Thus, it is necessary to consider the possibilities of permanent alopecia which may occur after chemotherapy.
Alopecia* ; Cyclophosphamide ; Drug Therapy ; Finasteride ; Hair ; Humans ; Minoxidil ; Retrospective Studies

PURPOSE: It has been reported in several for factors on the drug compliance of patients, number of drug being taken, symptom, and pharmaceutical dosage form. However, Studies of drug compliance by dosing methodologies of tamsulosin, finasteride combination therapy and symptom relief for benign prostatic hyperplasia has not been performed. Therefore, we studied for symptom and differences in medication adherence in method of administration of tamsulosin, finasteride combination therapy. MATERIALS AND METHODS: The groups were consisted in need of combination therapy of tamsulosin, finasteride on benign prostatic hyperplasia, one had packaged both drugs together (Group A, n=30) and the other were individually packaged both agents (Group B, n=30). International Prostatic Symptom Score (IPSS) were checked on first, 4weeks, and 8weeks. The evaluation was carried out of medicine compliance by checking the number of drugs 4weeks-interval. which was every 4weeks during 8weeks. RESULTS: The properties other than the PSA in both groups, there was no statistically significant differences between patients. In first 4weeks, drug compliance of each Group A and B had tamsulosin 82.6%, 93.3% (p=0.033), finasteride 80.1%, 93.3% (p=0.042), and last 4weeks tamsulosin 80.6%, 93.7% (p=0.013), finasteride 79.5%, 93.7% (p=0.002) were checked. Group C, D had 81.4%, 96.4% (p=0.021) on 4weeks, 80.6%, 97.2% (p=0.011) on 8weeks. CONCLUSIONS: For co-administration of finasteride and tamsulosin are required in patients with benign prostatic hyperplasia, in order to enhance drug compliance, both tablets have to prescript together in one package to be taken at one time is useful.
Compliance ; Dosage Forms ; Finasteride* ; Humans ; Medication Adherence* ; Prostatic Hyperplasia* ; Tablets

PURPOSE: We evaluated the sustained efficacy and the safety of finasteride and tamsulosin in combination in the treatment of benign prostatic hyperplasia. MATERIALS AND METHODS: In a retrospective trial, we evaluated men with symptomatic benign prostatic hyperplasia who were treated with a combination of finasteride and tamsulosin for 12 months. The international prostate symptom score (IPSS) and serum PSA were assessed at the baseline and at 6 and 12 months. Prostatic volume was measured at 0 and 12 months. RESULTS: Of the 210 men enrolled, 183 contributed data to the safety analysis, and 102 to the efficacy evaluation. Finasteride plus tamsulosin combination therapy produced statistically significant improvements in the urinary obstructive symptoms score and led to overall reduction from baseline of 9.8% in prostatic volume and 55% in serum PSA at the end of a 12-month trial. In men with prostatic volume greater than 30ml (n=28), a decrease in prostatic volume was higher than that less than 30ml (n=31) (13.1% vs. 6.9% from baseline respectively, p=0.0001, p=0.02). Treatment with finasteride plus tamsulosin for 12 months was generally well tolerated. CONCLUSIONS: Twelve months treatment with a combination of finasteride and tamsulosin was effective in improving urinary symptoms in men with benign prostatic hyperplasia and was well tolerated.
Finasteride* ; Humans ; Male ; Prostate ; Prostatic Hyperplasia* ; Retrospective Studies